Key Takeaways

  • Sun Pharma will acquire Organon in an all-cash deal valued at $11.75 billion, significantly expanding its global scale and product portfolio
  • The combined company will strengthen its position in women’s health, branded generics, and biosimilars, while increasing its focus on innovative medicines
  • The transaction, expected to close in early 2027, is projected to boost revenue, nearly double EBITDA and cash flow, and enhance long-term growth potential

Sun Pharmaceutical and Organon announced a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for $14 per share in cash, valuing the transaction at an enterprise value of approximately $11.75 billion.

The deal marks a significant strategic expansion for Sun Pharma, positioning the Indian drugmaker as a more diversified global pharmaceutical player with a stronger foothold in women’s health, biosimilars, and branded generics.

Sun's portfolio includes several ophthalmic drugs including Cequa (cyclosporine ophthalmic solution 0.09%) for increasing tear production in dry eye patients, BromSite (bromfenac 0.075%) for inflammation and pain after cataract surgery, and Xelpros (latanoprost 0.005%) for glaucoma.

Organon, which was spun off from Merck in 2021, has built a broad global presence with a portfolio of more than 70 products spanning women’s health, biosimilars, and general medicines. The company operates in over 140 countries, with key markets including the United States, Europe, China, Canada, and Brazil, supported by six manufacturing facilities across the European Union and emerging markets.

The acquisition aligns with Sun Pharma’s strategy to grow its medicines business while strengthening its established brands segment. The combined entity is expected to enhance Sun Pharma’s global scale and capabilities.

Upon completion, the merged company is projected to:

  • Rank among the top 25 global pharmaceutical companies, with combined revenues of approximately $12.4 billion
  • Become a leading player in branded generics and established medicines
  • Increase focus on innovative medicines, contributing about 27% of revenue
  • Emerge as a top 3 global company in women’s health
  • Enter the biosimilars segment as the 7th largest global player
  • Expand its footprint to 150 countries, including 18 major markets generating over $100 million each
  • Nearly double EBITDA and cash flow, enabling deleveraging from a post-transaction net debt/EBITDA ratio of 2.3x

Transaction Details

  • Sun Pharma will acquire 100% of Organon’s shares in cash
  • Financing will come from a mix of existing cash and committed bank funding
  • The transaction will be executed via a merger with a Sun Pharma subsidiary, with Organon continuing as the surviving entity
  • The deal has been approved by both companies’ boards
  • Closing is expected in early 2027, subject to regulatory approvals and shareholder consent